首页/数据集/miRNA expression screening in Liver X Receptor (NR1H3) agonist (GW3965) -treated differentiated Caco-2/TC7 cells

miRNA expression screening in Liver X Receptor (NR1H3) agonist (GW3965) -treated differentiated Caco-2/TC7 cells

ChEBI2016-06-03 更新2026-07-12 收录

microRNA表达谱分析

药物机制研究

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-MTAB-3675 数据链接链接失效反馈

官方服务：

资源简介：

miRNA expression screening in Liver X Receptor (NR1H3) agonist (GW3965) -treated differentiated Caco-2/TC7 cells

应用场景：

创建时间：

2016-06-03

基因本体富集分析

药物机制研究

This analysis was performed using the DAVID program (see MM). Count indicates the number of genes belonging to the indicated gene ontology biological processes that we found regulated by a factor 2; %

NIAID Data Ecosystem60

Gene expression signatures in oridonin-treated WT and R878H hematopoietic stem cells. Gene expression signatures in oridonin-treated WT and R878H hematopoietic stem cells

药物机制研究

干细胞生物学

Analysis of WT-Ctl v.s. WT-Ori and R878H-Ctl v.s. R878H-Ori hematopoietic stem cell (lineage-, c-kit+ Sca-1+ CD150+, CD34-). The four population of hematopoietic stem cell (HSC) were purified from the

NIAID Data Ecosystem60

Identification of genes involved in the anti-inflammatory effects of berberine in DNP-activated mouse MC/9 mast cells

肥大细胞免疫调控

药物机制研究

Atopic dermatitis is a common chronic inflammatory skin disease characterized by infiltration of inflammatory cells, extensive pruritus and a clinical course of symptomatic flares and remissions. Berb

NIAID Data Ecosystem50

Integrated omics profiling reveals FOXA1 and Ku70/Ku80 as the direct target of ivermectin for prostate carcinogenic inhibition

前列腺癌靶向治疗

药物机制研究

Here, we show that ivermectin suppress prostate cancer progression by inhibiting AR signaling pathway and attenuate cellular DNA damage repair capacity. We applied an integrated omics profiling includ

NIAID Data Ecosystem60

CDK4/6 inhibitors induce repication stress to cause long-term cell cycle withdrawal

细胞周期调控

药物机制研究

CDK4/6 inhibitors arrest the cell cycle in G1-phase. They are licenced to treat breast cancer and are also undergoing clinical trials against a range of other tumour types. To facilitate these efforts

NIAID Data Ecosystem60

miRNA expression screening in Liver X Receptor (NR1H3) agonist (GW3965) -treated differentiated Caco-2/TC7 cells

资源简介：

相关数据集